The stocks listed here trade at forward earnings multiples of less than 18.Valuations for many stocks are sky-high, and that can make now an unappealing time to invest in the stock market. However, there are still some great value buys that don't involve taking on a lot of risk or investing in unknown companies.Three of the best bargains you can buy today come from the healthcare sector. AstraZeneca (AZN +0.83%), CVS Health (CVS 0.13%), and Pfizer (PFE +0.04%) are all trading at incredibly low valuations wi ...

Key Points CVS Health is slowly righting the ship after several challenging years. Abbott Laboratories' strong business should improve thanks to an acquisition. Both healthcare leaders have attractive long-term prospects and solid dividend programs. 10 stocks we like better than CVS Health › No one knows how the stock market will unfold in 2026. Perhaps broader equities will experience significant volatility but perform well by the end of the year, just as they seem to be doing in 2025. Or maybe ...

Industry Overview - The healthcare sector is entering 2025 with challenges, particularly for managed care stocks like HMOs, due to high medical utilization, tighter reimbursement assumptions, and uncertainty around government-sponsored plans [1][3] - However, the industry is showing signs of recovery, with improved cost trends, better rate visibility, and insurers regaining control over margins as they adapt post-pandemic [2][8] Recent Developments - Higher-than-expected medical utilization has been a significant issue for HMOs, leading to recalibrated pricing and guidance from insurers [3] - Regulatory uncertainties regarding Medicare Advantage reimbursement have kept valuation multiples low, causing investors to remain cautious [3] Company Performance - UnitedHealth Group (UNH), Elevance Health (ELV), and Centene Corporation (CNC) faced sell-offs due to worsening medical-cost trends, while CVS Health (CVS) saw gains after delivering strong results and raising guidance [4][7] - UNH benefits from scale and integration with Optum, allowing it to normalize margins after earlier pressures [7][14] - CVS has improved cost controls and is leveraging its retail and pharmacy operations to enhance efficiency, positioning itself for growth in 2026 [15][16] Future Outlook - The sector is expected to become more investable as pricing discipline returns, scale advantages are reasserted, and demographic trends support steady demand [9][10][11] - The Zacks Consensus Estimate for UNH's 2026 earnings is $17.60 per share, reflecting an 8% growth from 2025 [15] - CVS's 2026 earnings estimate is $7.14 per share, indicating a 7.5% increase from 2025 [16] - Centene's 2026 earnings estimate is $2.94 per share, showing a significant 46.6% surge from 2025 [19]

DULUTH, Ga.--(BUSINESS WIRE)--Codoxo, the leading provider of AI and generative AI-powered healthcare payment integrity solutions, raised $35M in Series C funding, led by CVS Health Ventures. Echo Health Ventures joins the round as a new investor, with continued investment from existing investors including Sands Capital, 111 West Capital, Brewer Lane Ventures, Wipro Ventures, 450 Ventures (venture arm of Blue Cross and Blue Shield of Alabama) and QED Investors. This milestone brings Codoxo's to. ...

Core Viewpoint - The discussion highlights the volatility in the cryptocurrency market, particularly Ethereum, and suggests a cautious approach to investing while also considering profit-taking strategies in traditional stocks like General Motors and CVS [1]. Group 1: Cryptocurrency Insights - There is a warning about the risks of trying to time the market by picking bottoms in Ethereum, indicating that this strategy can lead to significant losses [1]. - The mention of adding to Ethereum holdings suggests a belief in its long-term potential despite short-term volatility [1]. Group 2: Stock Market Strategies - The conversation includes advice on taking profits from long positions in General Motors, indicating a strategy of capitalizing on gains [1]. - CVS is identified as a potential candidate for a bullish reversal, suggesting optimism about its future performance [1]. - There is a belief that Netflix may experience a bounce, indicating a positive outlook for the company in the near term [1].

Key Takeaways CVS began offering MMR vaccines in South Carolina, and the stock rose 2.4% following the announcement. CVS Health's Pharmacy and Consumer Wellness unit runs 9,000 sites and posted 12% revenue growth in Q3 2025. CVS' Aetna is rolling out a generative AI chat experience to help members navigate benefits more easily.CVS Health (CVS) has recently announced the offering of measles-mumps-rubella (MMR) vaccine to residents post the current outbreak in South Carolina. Both CVS Pharmacy stores and Minu ...

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.Below are the ratings of the most accurate analysts for three high-yield ...

Core Insights - The U.S. Federal Reserve has cut key interest rates by 25 basis points for the third time in 2025, which may lead investors to consider dividend stocks for stable income and enhanced returns [1] Group 1: Dividend Stocks Overview - Top Wall Street analysts have identified attractive dividend-paying stocks, which can assist investors in making informed decisions [2] Group 2: Devon Energy - Devon Energy (DVN) returned $401 million to shareholders in Q3 2025 through share repurchases and dividends, with a fixed quarterly dividend of $0.24 per share, yielding 2.5% [3] - JP Morgan analyst Arun Jayaram upgraded DVN to buy from hold, lowering the price target to $44 from $49, citing compelling valuation and free cash flow gains from a $1 billion optimization plan [4][5] - Devon achieved approximately 60% of its $1 billion optimization goal within six months, and Jayaram expects stable well productivity in 2026 and 2027 [5][6] - Jayaram is optimistic about Devon's acreage position in key regions and its potential for lower-risk, high-return drilling opportunities [7] Group 3: EOG Resources - EOG Resources (EOG) paid $545 million in dividends and repurchased $440 million in shares in Q3 2025, with a quarterly dividend of $1.02 per share, yielding 3.7% [9] - Siebert Williams Shank analyst Gabriele Sorbara reaffirmed a buy rating on EOG with a price target of $150, highlighting its ability to navigate commodity cycles and strong free cash flow generation [11] - EOG is committed to returning at least 70% of its free cash flow to shareholders, with the potential to return 100% based on its balance sheet strength [12] - The company is leveraging advanced technology to identify multiple development targets in the Delaware Basin and is ahead of its synergy targets from the Encino acquisition [13] Group 4: CVS Health - CVS Health (CVS) is undergoing a turnaround, expecting a mid-teens adjusted EPS CAGR through 2028, with a quarterly dividend of $0.665 per share, yielding 3.4% [15] - Mizuho analyst Ann Hynes reiterated a buy rating on CVS, raising the price target to $95, citing structural improvements in retail earnings [16] - CVS' mid-teens adjusted EPS CAGR target does not include potential share buybacks, which may occur once leverage targets are met [17] - The company anticipates a decline in the medical loss ratio by about 50 basis points in 2026, driven by better pricing and strategic exits from certain business segments [18] - CVS expects flat adjusted operating income growth in its Pharmacy and Consumer Wellness segment, improved by market share gains and cost savings [19]

But what's happening with this turnaround CBS Health. This stock has become the best performer in the healthc care sector under CEO David Joiner and shot up another 2% today as management laid out some bullish long-term earnings targets. Earlier today, we welcome David Joiner, the president CEO of CVS Health to find out more.Check it out. David, some people come on, they got a narrative. They tell you some story and you get excited and then it doesn't doesn't happen.You I believe are actually transforming t ...

Unvaccinated residents can receive a measles vaccine at select CVS Pharmacy and MinuteClinic locations across the state WOONSOCKET, R.I., Dec. 11, 2025 /PRNewswire/ -- As South Carolina public health officials work to stop the spread of measles following the current outbreak in the state, CVS Health® (NYSE:CVS) is offering the measles-mumps-rubella (MMR) vaccine to residents. Both CVS Pharmacy® stores and MinuteClinic® walk-in medical clinics in the area have vaccines available to help protect patients agai ...